Antiretroviral therapy (ART) effectively replenishes depleted CD4 cells, thereby reducing TB risk by 67% and halving TB recurrence rates [11–14], together with the World Health Organization (WHO) recommended TB preventive treatment (TPT) [15, 16]. Here, CD4 is linked to tuberculosis.